The results showed that high mRNA levels of ERBB2 and ERBB4 in glioma patients were associated with a poor prognosis (Fig. 8c, d, g and h), while the expression of EGFR and ERBB3 had no correlation with the prognosis of glioma patients (Fig. 8a, b, e and f). This evidence concerns the gene EGFR and central nervous system cancer.